Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice by Salyka Sengsayadeth, Bipin N. Savani, Olalekan Oluwole, Bhagirathbhai Dholaria

Get full text

CAR T cell therapy in solid tumors: A review of current clinical trials by Urvi Patel, John Abernathy, Bipin N Savani, Olalekan Oluwole, Salyka Sengsayadeth, Bhagirathbhai Dholaria

Get full text

P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 A... by Olalekan Oluwole, Markqayne Ray, Neil Davies, Rory Bradford, Calum Jones, Anik Patel, Frederick Locke

Get full text

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy by Jiun-Ruey Hu, Ameet Patel, Shi Huang, Yan Ru Su, Kimberly B. Dahlman, Kelsey Tomasek, Yueli Zhang, Richard T. O’Neil, Jamye F. O’Neal, Isik Turker, Douglas B. Johnson, Joe-Elie Salem, Javid J. Moslehi, Olalekan Oluwole

Get full text

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA... by Javier Munoz, Frederick Locke, Lazaros Lekakis, Herbert Eradat, Michael Tees, Sven de Vos, Rajneesh Nath, Don Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan Oluwole, Miguel-Angel Perales, David Miklos, Paul Fisher, Lovely Goyal, Lynn Navale, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Neelapu

Get full text